Sun set to rise in the East with new Ilumya filing

2 August 2019
sunpharma-big

In Japan, a new filing for marketing approval for the monoclonal antibody tildrakizumab-asmn has been lodged, for the treatment of moderate-to-severe psoriasis and psoriatic arthritis.

Marketed in the USA as Ilumya, Indian pharma major Sun Pharmaceutical Industries (BSE: 524715) submitted data with the Pharmaceuticals and Medical Devices Agency (PMDA) with the goal of expanding the franchise for the product.

Ilumya faces a significantly crowded field for interleukin (IL)-23 blockers and related competitors, a market that was opened up by Johnson & Johnson’s (NYSE: JNJ)  launch of Tremfya (guselkumab) in 2017.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology